Peptides Academy
Teriparatide
Eli Lilly (Forteo/Forsteo)
Teriparatide is the biologically active 1-34 fragment of human parathyroid hormone (PTH), produced by recombinant technology and marketed most widely as Forteo (Forsteo in Europe). Unlike most osteoporosis drugs, which are antiresorptive — they slow the breakdown of bone — teriparatide is anabolic: it actively stimulates osteoblasts to build new bone. This distinction is the reason it is reserved for people at high or very high risk of fracture, such as those with severe osteoporosis, multiple prior fractures, or a poor response to other therapies. The key to its effect is how it is dosed. Continuously elevated PTH (as in hyperparathyroidism) drives bone loss, but PTH delivered as a brief daily pulse paradoxically favors bone formation over resorption — an effect known as the anabolic window. Teriparatide exploits this by being injected once daily, producing a transient PTH signal that increases bone mineral density, particularly in the spine, and reduces the risk of vertebral and non-vertebral fractures in clinical trials. Teriparatide is a genuine, approved prescription medicine — not a research or grey-market peptide. Its use is time-limited (courses are generally capped at around two years over a lifetime), it requires medical supervision and monitoring of calcium, and it is typically followed by an antiresorptive agent to preserve the bone gained. This entry is educational reference material about an established osteoporosis therapy, and any decision to use it belongs with a treating clinician.
Specifications
| Origin / Manufacturer | Recombinant human PTH(1-34) |
| Active Components | Teriparatide (rhPTH 1-34) |
| Storage | Refrigerated (2-8°C); pen device kept cold between uses per label |
| Shelf Life | Per manufacturer labeling (typically ~28 days in-use after first injection) |
| Form Factor | Prefilled multidose subcutaneous pen injector |
Clinical Evidence
Clinical report reference
Frequently Asked Questions
Reviewed by
Peptides Academy Editorial
Editorial Team
All clinical claims cross-checked against primary sources. Read our editorial policy →
Related Peptides
Abaloparatide
Pharmaceutical-Grade
Abaloparatide (trade name Tymlos) is a 34-amino acid synthetic peptide analog of human parathyroid hormone-related protein (PTHrP) approved by the FDA in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It selectively activates the PTH1 receptor in its RG (G-protein-dependent) conformation, promoting robust anabolic bone formation with comparatively less bone resorption and hypercalcemia than teriparatide (PTH 1–34). In the pivotal ACTIVE trial, abaloparatide demonstrated significant reductions in vertebral and nonvertebral fractures, establishing it as a potent osteoanabolic agent in the management of severe osteoporosis.
Calcitonin (Salmon)
Various (Miacalcin/Fortical)
A synthetic version of the salmon calcitonin hormone, approved as a nasal spray or injection that lowers blood calcium and reduces bone breakdown, historically used for osteoporosis, Paget's disease of bone, and hypercalcemia.
Gonadorelin
Research-Grade
A synthetic analog of endogenous GnRH (gonadotropin-releasing hormone) used clinically to evaluate pituitary gonadotropin reserve and investigated for fertility and hormonal optimization protocols.